Stockreport

Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF -- 93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response ---- Findings Support Regulatory Filings [Read more]